Capstone Therapeutics Corp banner
Financial profile · FY2019

A pre-commercial biotech with episodic licensing receipts and recurring cash burn

The supplied history shows no recurring product-revenue base, while operating costs have generally exceeded revenue and operating cash flow. A disclosed license payment was episodic, leaving operations dependent on external funding rather than a self-funding product business.

What the latest results confirm

The 2019 results maintain the established loss-making, cash-consuming pattern after an isolated positive operating-cash-flow year; no recurring revenue base emerged. This leaves funding, rather than internally generated cash, central to sustaining development and operations.

What matters next

Whether new funding or license-related receipts replenish cash sufficiently to cover operating needs and near-term liabilities.

USD
Metric FY2010 FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 FY2017 FY2018 FY2019
(10.9m) (9.7m) (4.1m) (4.1m) (4.2m) (2.8m) (1.6m) (1.8m) (380k) (2.7m)
140k 120k 30k 170k 160k 157k 179k 205k 157k 39k
0 0 0 0 — — — — — —
275k 159k 107k — — — — — — —
280k 160k 110k 30k 53k 174k 35k 68k 253k 262k
(230k) (1.2m) 550k (40k) (140k) 287k 136k (79k) 36k 734k
(10.7m) (10.6m) (3.4m) (4m) (4.1m) (2.2m) (1.3m) (1.6m) 66k
(60k) (20k) (380k) 0 — — — — — —
22.3m 0 170k 0 0 0 0 0 0 0
22.2m (20k) (210k) 0 0 0 0 0 0 0
0 0 0 0 — — 946k 1m 0 —
— — — — — 1m 0 1.1m 0 350k
— — — — 0 — — (15k) 0 46k
0 0 0 0 0 1m 946k 2.1m 0 396k
11.5m (10.6m) (3.6m) (4m) (4.1m) (1.2m) (313k) 577k 66k (1.3m)
(10.8m) (10.6m) (3.8m) (4m) (4.1m) (2.2m) (1.3m) (1.6m) 66k